Replies to post #136149 on NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

Yes Flipper you are absolutely right!

Relating to this subject there is something else puzzling me about the release of the separate 8K sec filing form on the 22nd.

Why did NWBO release a separate 8K sec filing to state they are anticipating (interim) blinded data if they have never done so before. Did NWBO release an 8K sec filing X-time before June 5 because it was anticipating the publication of (interim) blinded data as presented by Dr Bosch? NO.

Of course we have seen press releases announcing the presentation of blinded data and the presentation of the blinded data itself afterward, but SEC laws are very clear in disguising between a press release and SEC Filing. As the SEC explains it, “the types of information required to be disclosed on Form 8-K are generally considered to be ‘material,’” … [meaning] “there is a substantial likelihood that a reasonable investor would consider the information important in making an investment decision.” See http://westwickepartners.com/2014/10/form-8-k-and-press-releases-know-the-difference-when-you-disclose-news/

The publication of blinded data is not much of a big deal and absolutely also does not require a quiet time or canceling of a sponsored conference...So if its not obligatory to release an 8K sec filing to announce one is ANTICIPATING the publication (or publication afterward for that matter) of just that blinded data because its not material, then why did NWBO all over sudden felt it was obligated to release an 8K sec for?

I Think Flipper… because it confirms our theory… IMHO

[Doc logic]

flipper44,

OS must stay blinded to get full reimbursement credit. If for example 50 unevented patients are currently beyond the moving OS and 40 are closing in on it, with most expected to pass it, then the potential to move the current moving median out significantly is not something NWBO would want to leave on the table. FDA and the DMC may long ago have been satisfied with efficacy but the questions of how much, with which additional treatments and in which tumor types would have remained especially if anti PD-1 treatments were added in to the treatment regimen of some later patients. More time for OS will reveal a much clearer big picture. In the mean time NWBO knows there must be other news venues to make up for the lack of the conference presentation or the silence will be relentlessly hammered. Best wishes.